599 results about "Bicarbonate" patented technology

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

The invention discloses polyether-ether-ketone resin with adjustable molecular weight distribution as well as a synthesis method and application of the polyether-ether-ketone resin. The synthesis method comprises the following steps: preparing polyether-ether-ketone resin in the presence of carbonate and / or bicarbonate of alkali metal; wherein the carbonate and / or bicarbonate of the alkali metal comprises sodium carbonate and potassium carbonate, and the sodium carbonate has gradient particle size distribution. According to the invention, sodium carbonate with specific particle size distribution is used to regulate and control the reaction rate to be stable and continuous, so that the molecular weight distribution of the polymer presents a narrower distribution form. Therefore, the molecular structure is uniform, the molecular form is uniform, the physical and chemical properties, including mechanical strength, thermal stability and chemical stability, of the material can be improved, and particularly, the thermal stability of the material is improved most remarkably.

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

The invention discloses a deep-eutectic solvent for oil-containing solid waste treatment, an inorganic base and CO2 double-circulation oil-solid separation method based on the deep-eutectic solvent and the deep-eutectic solvent for oil-containing solid waste treatment. The deep-eutectic solvent for oil-containing solid waste treatment is characterized in that branched or cyclic short-chain fatty acid with pKa being 4-6 is used as a hydrogen bond donor; a phenol derivative with pKa being 9-11 or C6-C8 straight-chain alcohol is used as a hydrogen bond acceptor; the ratio of the hydrogen bond donor to the hydrogen bond acceptor is (5: 1)-(1: 5) according to the molar ratio of the hydrogen bond donor to the hydrogen bond acceptor; the regulation and control method based on the deep-eutectic solvent comprises the following steps: (1) reacting inorganic alkali with the deep-eutectic solvent to form a hydrophilic carboxylate and phenate solution; (2) after CO2 is introduced, fatty acid / phenols are collected to form a hydrophobic deep-eutectic solvent again, and meanwhile, a bicarbonate aqueous solution is obtained; and (3) heating the bicarbonate aqueous solution or introducing N2, removing CO2, and forming hydrophilic carboxylate and phenolate again by the eutectic solvent in the formed alkaline carbonate solution. According to the inorganic base and CO2 double-circulation oil-solid separation method based on the eutectic solvent, the eutectic solvent can be recycled.

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

The present invention relates to a pharmaceutical composition comprising a weak acid drug, with the use of a bicarbonate salt to achieve a high incorporation of the drug into the liposome and a better therapeutic efficacy. Also disclosed is a method for treating a respiratory disease using the pharmaceutical composition disclosed herein.

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

The invention relates to the technical field of fireproof materials, and discloses a flame retardant for fireproof paint and a preparation method of the flame retardant. The flame retardant is prepared from modified aluminum polyphosphate, a borate-phosphate composite acid source, a silica modified carbon forming agent, chitosan modified nano carbon, melamine cyanurate, bicarbonate, graphene oxide, nano titanium dioxide and an interface reinforcing agent. Through the multi-stage catalysis of the composite acid source, the efficient charring of the modified charring agent, the multi-stage gas source release and the synergistic effect of the nano additive, a compact and uniform expansion layer is formed, and the high-temperature stability, the heat insulation performance and the thickness retention rate in a dynamic environment of the expansion layer are remarkably improved. According to the preparation method, by optimizing the steps of mixing, dispersing, drying and curing the components, the high-efficiency exertion of the performance of the flame retardant is ensured. The flame retardant is widely applicable to fireproof coatings for buildings, steel structures, wood and the like, has the characteristics of high expansion efficiency, lasting heat insulation and excellent mechanical properties, and effectively overcomes the defects in the prior art.

The additive 50 is used alone as a tablet or capsule, or together with a base product 54, to produce an enhancing product 52 that provides a health benefit 34 to a person 20 ingesting or using the additive 50, the additive 50 including an enzyme that stimulates the naturally occurring in the human body. The additive 50 has one or more hydrogenated substances 58, such as erythritol 58a, xylitol 58b, hydrogenated dihydromyricetin 58c and / or quercetin dihydrate 58d, and a flavonoid dihydromyricetin 14a. The flavonoid 14 may be extracted from Ampelopsis grossedentata plant 17 and / or a plant 16 selected from the genus Hovenia (e.g., Japanese raisin tree). The additive may also have one or more solvents 60, such as a bicarbonate compound 60a or an alcohol solvent 60b, a pH balanced acid 62, and / or a preservative 64. The base product 54 may be a liquid 66, a solid 68, a powder 70, a chew 72, a medicament 74, a cosmetic 76, or an emulsion or other coating product 78. The reinforced product 52 is a base product 54 reinforced by an additive.

The present invention relates to a pharmaceutical composition comprising a weak acid drug, with the use of a bicarbonate salt to achieve a high incorporation of the drug into the liposome and a better therapeutic efficacy. Also disclosed is a method for treating a respiratory disease using the pharmaceutical composition disclosed herein.

Disclosed herein are dosage forms comprising a combination of: 1) an active pharmaceutical ingredient (API), 2) a cyclodextrin, and 3) a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the drug for the treatment of conditions such as pain.

The invention relates to the technical field of gene engineering and recombinase catalysis engineering, in particular to a recombinant strain for expressing phenolic acid decarboxylase as well as a construction method and application of the recombinant strain. According to the invention, a recombinant strain for expressing the phenolic acid decarboxylase PADCs is constructed by heterologous expression of a coding gene PADCs of the phenolic acid decarboxylase. The enzyme liquid of the recombinant strain for expressing the phenolic acid decarboxylase has remarkable catalytic performance, p-coumaric acid can be used as a substrate, the recombinant strain is used for inducing expression, the purified enzyme liquid is used for catalyzing decarboxylation reaction of p-coumaric acid, and p-hydroxystyrene is synthesized; meanwhile, the phenolic acid decarboxylase PADCs has a wide substrate spectrum, the 4-vinylphenol compound can be used as a substrate, bicarbonate is used as a carboxyl source, the freeze-dried whole cell of the recombinant strain is utilized to catalyze the 4-vinylphenol compound to carry out regioselective beta-carboxylation reaction, a series of phenolic acids with biological activity are synthesized by an enzymic method, and meanwhile CO2 is immobilized; and a huge application potential is provided for the utilization of CO2.

The invention relates to the technical field of water treatment, in particular to a nanofiltration membrane and a preparation method thereof. The preparation method comprises the following steps: soaking a base membrane in a water phase solution, taking out the base membrane, performing surface drying, coating the base membrane with an oil phase solution, performing interfacial polymerization reaction, and curing to obtain the nanofiltration membrane, the water-phase solution comprises a polyamine monomer, a surfactant, an acid-binding agent and water; the acid binding agent is bicarbonate; the oil phase solution comprises an acyl chloride monomer, an organic solvent a and an organic solvent b; the organic solvent a is ethyl cyclohexane; the organic solvent b comprises at least one of methane chloride, monochloroethane, diethyl ether, methyl ethyl ether, dimethyl ether and methyl formate. The membrane flux is improved while the acid chemical cleaning resistance of the membrane is improved.

The invention discloses sprayable hydrogel for healing a bacterial infected wound and a preparation method of the sprayable hydrogel. The preparation method comprises the following steps: preparing a g-C3N4 nanosheet by taking melamine as a precursor, and then preparing AuNPs-C3N4 nano-enzyme on the g-C3N4 nanosheet through in-situ reduction of HAuCl4. 3H2O; preparing oxidized hyaluronic acid through a sodium periodate oxidation method; the preparation method comprises the following steps: incubating an AuNPs-C3N4 nano-enzyme solution and a glucose solution, adding a Mn < 2 + >-containing manganese salt solution and a bicarbonate solution, then mixing with an oxidized hyaluronic acid solution to obtain a dispersion liquid, spraying the dispersion liquid and a carboxymethyl chitosan solution in a cross-phase manner, and carrying out a Schiff base reaction to prepare the AuNPs-C3N4 / Glu / Mn < 2 + >-carboxymethyl chitosan-OHA hydrogel. The method is simple in preparation process, and the prepared hydrogel can have excellent in-vitro antibacterial efficiency, good biocompatibility and bacterial adsorbability, and can effectively remove bacteria at wound infection parts and promote wound healing.

This application relates to the field of ceramsite, and specifically discloses a process method for producing coal gangue ceramsite by microwave drying, which includes the following steps: Coal gangue pretreatment: Granulate coal gangue powder and bicarbonate under the action of a wetting agent to form green coal gangue balls, and dry the green coal gangue balls with microwave; 90 - 100 parts of coal gangue powder, 1 - 4 parts of bicarbonate, 3 - 8 parts of wetting agent; The wetting agent includes raw materials in the following weight parts: 1 - 3 parts of polyvinyl alcohol, 1.5 - 4 parts of sodium carboxymethylcellulose, 0.5 - 1 part of surfactant; Coal gangue ceramsite preparation: After pyrolysis, decarbonization, sintering, and cooling of the dried green coal gangue balls, ceramsite is formed; Pyrolysis includes: Gradient oxygen-controlled pyrolysis of the dried green coal gangue balls, the pyrolysis temperature is 250 - 450 °C, and at the same time, air flow is intermittently introduced to impact the material layer. This method can significantly reduce the bursting rate of ceramsite, the surface of the ceramsite has no cracks, the strength is high, and the product quality is excellent.

The disclosure relates to a method including determining a treatment time of a dialysis treatment for a patient, receiving, from at least a sensor of a dialysis machine, a dialysate flow rate, the dialysate comprising bicarbonate pumped out of a bicarbonate source, wherein the bicarbonate source has an initial amount of bicarbonate, and predicting that by end of the dialysis treatment no more than a threshold amount of bicarbonate will be left in the bicarbonate source, and in response, determining that a clearance value during the treatment is or will be higher than the threshold clearance value, and sending, to a balancing system, an instruction to reduce the dialysate flow rate to a reduced rate, wherein the reduced rate results in reducing a rate of bicarbonate pumped out of the bicarbonate source while maintaining a clearance value of the treatment at no less than the threshold clearance value.

A method for regenerating a bis(iminoguanidine) (BIG) carbon dioxide sorbent, the method comprising: (i) providing a carbonate or bicarbonate salt of the BIG carbon dioxide sorbent, and (ii) directly contacting the carbonate or bicarbonate salt of the BIG carbon dioxide sorbent with steam heated to a temperature within a range of 80°C-130°C to result in regeneration of the BIG carbon dioxide sorbent with simultaneous conversion of the carbonate or bicarbonate anions into carbon dioxide, wherein the regenerated BIG carbon dioxide sorbent is substantially removed of carbonate or bicarbonate and may optionally contain one or more adduct water molecules. In some processes, the regenerated BIG carbon dioxide sorbent is dissolved in water condensing from the steam during the contacting step to form an aqueous solution of the regenerated BIG carbon dioxide sorbent.

The disclosure relates to a dialysis machine that comprises a dialyzer, a fluid source, a first line connected to the fluid source, and a container containing bicarbonate. The container connects to the first line and the fluid flows from the fluid source, through the first line, to the container. The dialysis machine further includes a second line connected to the container, a flow rate sensor connected to at least one of the lines, a pressure sensor configured for detecting fluid pressure of the container, a display, and a data processing apparatus. The data processing apparatus is configured to receive signals from the flow rate sensor and the pressure sensor. The data processing apparatus is configured to calculate a size of the container based on the received signals.

The invention relates to the field of gene engineering, in particular to a phenolic acid decarboxylase mutant and application thereof. According to the invention, tryptophan at the 30th site of phenolic acid decarboxylase PADCs from Clostridium sp.DSM 8431 is mutated into leucine, and tyrosine at the 136th site of the phenolic acid decarboxylase PADCs is mutated into tryptophan, so that the phenolic acid decarboxylase mutant is obtained. The phenolic acid decarboxylase mutant can catalyze decarboxylation reaction of p-coumaric acid to synthesize p-hydroxystyrene; and hydrocarbonate can also be used as a carboxyl source to catalyze carboxylation reaction of p-hydroxystyrene to synthesize p-coumaric acid. The phenolic acid decarboxylase PADCs has the enzyme activity characteristics of excellent temperature stability and acetonitrile stability, still retains more than 80% of decarboxylase activity after being incubated for 2 hours at 55 DEG C, still retains about 36% of decarboxylase activity after being incubated for 2 hours in acetonitrile with the volume fraction of 50%, can remarkably improve the yield of p-coumaric acid, can reach 13.05 mM when the substrate concentration is 80 mM, and is improved by 74% compared with original phenolic acid decarboxylase PADCs; the method has a wide industrial application prospect and CO2 fixation potential.

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

The invention provides a synthesis method of (3-hydroxyadamantane-1-methoxycarbonyl) difluoromethanesulfonate photoacid generator anions, and relates to a photoacid generator anion synthesis method of (3-hydroxyadamantane-1-methoxycarbonyl) difluoromethanesulfonate photoacid generator anions. The preparation method comprises the following steps: S1, uniformly mixing a solvent and difluorobromoacetic acid, then adding CDI, fully stirring, then adding 3-hydroxy-1-adamantane methanol, fully reacting, then adding bicarbonate, carrying out liquid separation to obtain an organic phase A, washing the organic phase A, and carrying out drying and spin-drying; s2, fully mixing the spin-dried substance with NaHCO3, Na2S2O4, acetonitrile and ultrapure water, then carrying out liquid separation to obtain an organic phase B, and carrying out drying and spin-drying on the organic phase B; and S3, dissolving the spin-dried substance in water, then adding an H2O2 solution, carrying out a full reaction, and then carrying out cooling and post-treatment so as to obtain the photoacid generator anions. According to the method, 3-hydroxy-1-adamantane methanol and difluorobromoacetic acid are used as reaction raw materials, esterification reaction is performed under the condition of adding CDI to obtain a first-step reaction intermediate, then acylation sulfonation and oxidation reaction are performed to obtain the target product photoacid generator anion, the reaction process is mild in condition, and the product purity is high.